Phase 3 findings show infigratinib significantly improved annualized height velocity vs placebo in children living with achondroplasia. Topline data were announced from a phase 3 trial evaluating ...

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to narrowing of the skeletal structures surrounding the spinal cord. Despite ...

Please provide your email address to receive an email when new articles are posted on . Children with achondroplasia achieved 1.49 cm per year greater increase in annualized growth velocity with ...

Please provide your email address to receive an email when new articles are posted on . Navepegritide is the first once-weekly therapy approved by the FDA to increase growth for children with ...

A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical ...

Achondroplasia is a genetic condition that affects the body’s ability to convert cartilage into bone, resulting in short limbs. The condition is caused by changes to the FGFR3 gene, which can pass ...

Achondroplasia is a rare genetic disorder that causes short stature and bowed legs. It is the result of a genetic mutation that is more likely to arise in the children of older men. In this article, ...

Dwarfism often happens because of genetic or inherited conditions. Achondroplasia is the most common form of dwarfism, accounting for about 70% of cases. People with achondroplasia have a relatively ...

Achondroplasia is a genetic bone growth disorder that causes disproportionate dwarfism, where individuals develop short limbs and a torso of typical size. It occurs in roughly 1 in 20,000 to 30,000 ...

SEATTLE -- Once-weekly navepegritide and lonapegsomatropin boosted growth in children with achondroplasia, the most common form of dwarfism, according to interim findings from a small phase II trial.

What Is It, and Why Does It Matter? Yuviwel (navepegritide) is a once-weekly shot for children 2 and older with achondroplasia who still have open growth plates. It is approved by the FDA to help ...